||1. Mort, R.L., I.J. Jackson, and E.E. Patton, The melanocyte lineage in development and disease (vol 142, pg 620, 2015). Development, 2015. 142(7): p. 1387-1387.|
2. Tsao, H., et al., Melanoma: from mutations to medicine. Genes & Development, 2012. 26(11): p. 1131-1155.
3. Klicks, J., et al., A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells. BMC Cancer, 2019. 19(1): p. 402.
4. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 2019. 69(1): p. 7-34.
5. Hodis, E., et al., A landscape of driver mutations in melanoma. Cell, 2012. 150(2): p. 251-63.
6. Gandini, S., et al., Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer, 2005. 41(14): p. 2040-59.
7. Thompson, J.F., R.A. Scolyer, and R.F. Kefford, Cutaneous melanoma. Lancet, 2005. 365(9460): p. 687-701.
8. Hodis, E., et al., A Landscape of Driver Mutations in Melanoma. Cell, 2012. 150(2): p. 251-263.
9. Huang, F.W., et al., Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013. 339(6122): p. 957-959.
10. Forbes, S.A., et al., The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet, 2008. Chapter 10: p. Unit 10 11.
11. Sosman, J.A., et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med, 2012. 366(8): p. 707-14.
12. Halaban, R., et al., PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res, 2010. 23(2): p. 190-200.
13. Heideman, D.A., et al., KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn, 2012. 14(3): p. 247-55.
14. Dossett, L.A., R.R. Kudchadkar, and J.S. Zager, BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf, 2015. 14(4): p. 559-70.
15. Achkar, T. and A.A. Tarhini, The use of immunotherapy in the treatment of melanoma. Journal of Hematology & Oncology, 2017. 10.
16. Rock, R., et al., BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. Sci Adv, 2019. 5(8): p. eaav8463.
17. Swaika, A., J.A. Crozier, and R.W. Joseph, Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Design Development and Therapy, 2014. 8: p. 775-787.
18. Joseph, E.W., et al., The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America, 2010. 107(33): p. 14903-14908.
19. Chapman, P.B., et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011. 364(26): p. 2507-16.
20. Wagle, N., et al., Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol, 2011. 29(22): p. 3085-96.
21. Gencler, B. and M. Gonul, Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature. Dermatol Res Pract, 2016. 2016: p. 5361569.
22. Adelmann, C.H., et al., Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget, 2016. 7(21): p. 30453-60.
23. Oberholzer, P.A., et al., RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol, 2012. 30(3): p. 316-21.
24. Boussemart, L., et al., Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol, 2013. 24(6): p. 1691-7.
25. Su, F., et al., RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med, 2012. 366(3): p. 207-15.
26. Hatzivassiliou, G., et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 2010. 464(7287): p. 431-5.
27. Jordan, E.J. and C.M. Kelly, Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother, 2012. 13(17): p. 2533-43.
28. Nijenhuis, C.M., et al., Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? Cancer Treat Rev, 2013. 39(4): p. 305-12.
29. Su, F., et al., Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res, 2012. 72(4): p. 969-78.
30. Rughani, M.G., A. Gupta, and M.R. Middleton, New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol, 2013. 5(1): p. 73-80.
31. Colombo, M., G. Raposo, and C. Thery, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol, 2014. 30: p. 255-89.
32. Zhang, H.G. and W.E. Grizzle, Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol, 2014. 184(1): p. 28-41.
33. Enderle, D., et al., Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. PLoS One, 2015. 10(8): p. e0136133.
34. Nawaz, M., et al., The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat Rev Urol, 2014. 11(12): p. 688-701.
35. Vader, P., et al., Extracellular vesicles for drug delivery. Adv Drug Deliv Rev, 2016. 106(Pt A): p. 148-156.
36. Lai, C.P., et al., Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun, 2015. 6: p. 7029.
37. Yao, Z., et al., RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med, 2019. 25(2): p. 284-291.
38. Wendler, F., et al., Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. Oncogene, 2017. 36(7): p. 877-884.
39. Andrade, L.N.S., et al., Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy. Sci Rep, 2019. 9(1): p. 14482.
40. Roh, M.R., et al., Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. J Dermatol, 2015. 42(9): p. 881-8.
41. Luke, J.J. and F.S. Hodi, Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res, 2012. 18(1): p. 9-14.
42. Zhang, C., et al., RAF inhibitors that evade paradoxical MAPK pathway activation. Nature, 2015. 526(7574): p. 583-6.
43. Tutuka, C.S.A., et al., PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. Mol Cancer, 2017. 16(1): p. 112.
44. Gast, C.E., et al., Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv, 2018. 4(9): p. eaat7828.
45. Arozarena, I. and C. Wellbrock, Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer, 2019. 19(7): p. 377-391.
46. Gagliardi, M., et al., Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis, 2019. 10(12): p. 902.
47. Catalano, M. and L. O′Driscoll, Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles, 2019. 9(1): p. 1703244.
48. Kavanagh, E.L., et al., Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells. Oncogenesis, 2017. 6(10): p. e388.
49. Becker, A., et al., Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell, 2016. 30(6): p. 836-848.
50. Kodet, O., et al., Melanoma cells influence the differentiation pattern of human epidermal keratinocytes. Mol Cancer, 2015. 14: p. 1.
51. Sunkara, V., H.K. Woo, and Y.K. Cho, Emerging techniques in the isolation and characterization of extracellular vesicles and their roles in cancer diagnostics and prognostics. Analyst, 2016. 141(2): p. 371-81.
52. Raposo, G. and W. Stoorvogel, Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol, 2013. 200(4): p. 373-83.
53. Chen, J., C. Hu, and P. Pan, Extracellular Vesicle MicroRNA Transfer in Lung Diseases. Front Physiol, 2017. 8: p. 1028.